Exact Therapeutics (Norway) Investor Sentiment

EXTX Stock  NOK 3.48  0.02  0.57%   
About 62% of Exact Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Exact Therapeutics AS suggests that many traders are alarmed regarding Exact Therapeutics' prospects. Exact Therapeutics' investing sentiment shows overall attitude of investors towards Exact Therapeutics AS.
Exact Therapeutics stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Exact daily returns and investor perception about the current price of Exact Therapeutics AS as well as its diversification or hedging effects on your existing portfolios.
  
over two weeks ago at news.google.com         
Summit Therapeutics Inc. Among the Stocks That Will Go to the Moon According to Analysts - Yahoo Fin...
Google News at Macroaxis
over three weeks ago at news.google.com         
Exact Sciences Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Google News at Macroaxis
over a month ago at news.google.com         
Windtree Therapeutics, Inc. Announces Reverse Stock Split - Yahoo Finance
Google News at Macroaxis
over a month ago at news.google.com         
Exact Sciences Expected to Beat Earnings Estimates Can the Stock Move Higher - Nasdaq
Google News at Macroaxis
over a month ago at news.google.com         
Exact Therapeutics and Cordance Medical Announce Early Encouraging Data in Brain Cancer Mice Model -...
Google News at Macroaxis
over a month ago at news.google.com         
EXACT Therapeutics and Cordance Medical Achieve Breakthrough in Brain Cancer Treatment - TipRanks
Google News at Macroaxis
over two months ago at news.google.com         
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes - GlobeNewswire
Google News at Macroaxis
over three months ago at news.google.com         
Exact Therapeutics Announces Fda Clearance of Ind for Enact, A Phase 2 Trial in Pancreatic Cancer - ...
Google News at Macroaxis
over three months ago at news.google.com         
EXACT Therapeutics Secures NOK 145 Million in Private Placement - TipRanks
Google News at Macroaxis
over three months ago at news.google.com         
EXACT Therapeutics Expands Share Capital for Growth - TipRanks
Google News at Macroaxis
over three months ago at news.google.com         
Shareholders in Intellia Therapeutics have lost 88, as stock drops 4.7 percent this past week - Simp...
Google News at Macroaxis
over three months ago at news.google.com         
EXACT Therapeutics AS Notice of extraordinary general meeting - Finansavisen
Google News at Macroaxis
over three months ago at news.google.com         
EXACT Therapeutics and GE HealthCare Partner in Cancer Therapy - TipRanks
Google News at Macroaxis
over three months ago at news.google.com         
Neurogenes Rett Syndrome Gene Therapy Shows Breakthrough Results in Early Trial NGNE Stock News - St...
Google News at Macroaxis
over three months ago at news.google.com         
Neurogene Announces Oversubscribed 200 Million Private Placement - BioSpace
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Exact Therapeutics that are available to investors today. That information is available publicly through Exact media outlets and privately through word of mouth or via Exact internal channels. However, regardless of the origin, that massive amount of Exact data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Exact Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Exact Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Exact Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Exact Therapeutics alpha.

Exact Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Other Information on Investing in Exact Stock

Exact Therapeutics financial ratios help investors to determine whether Exact Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Exact with respect to the benefits of owning Exact Therapeutics security.